Skip to main content

Advertisement

SpringerLink
Log in

Risk reduction surgery (RRS) for tubo-ovarian cancer in an Irish gynaecological practice: an analysis of indications and outcomes

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Background

High-grade serous carcinoma (HGSC) is the most common tubo-ovarian cancer. The fallopian tube harbours the precursor lesion: serous tubal intraepithelial carcinoma (STIC). Bilateral salpingo-oophorectomy is an effective risk-reducing surgical (RRS) strategy for breast cancer susceptibility gene mutation carriers (BRCAm). The value of RRS in those without defined genetic risk is unknown but these women represent a substantial cohort in prophylactic surgical practice.

Methods

This is a retrospective review of RRS at an Irish university teaching hospital.

Results

One hundred and thirty women underwent RRS; group 1 = 46 BRCAm; group 2 = 19 BRCAm negative/65 genetic status unknown. Group 1 had one occult HGSC. Group 2 had no STIC or cancers and were older and more likely to have hysterectomy and benign pathology. Other pathologies included serous tubal intraepithelial lesions (STIL) (2), p53 signatures (2), endometriosis (6), fibroids/adenomyosis (4) and atypical endometrial hyperplasia (1).

Conclusion

More than 60% of women undergoing RRS were BRCAm negative or untested. Counselling of high-risk women without defined germline mutations remains a challenge for gynaecologists because the likelihood of removing STIC lesions or occult invasive cancer is low. Removal of coincidental pathology may give added value to RRS in these women.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Green AE, Garcia AA, Ahmed S (2014) Ovarian cancer. Available at: http://emedicine.medscape.com/article/255771-overview http://emedicine.medscap

  2. Ovarian Cancer Statistics. National Cancer Registry Ireland. Available at: www.ncri.ie

  3. Barnholz-Sloan JS, Schwartz AG, Qureshi F et al (2003) Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 189(4):1120–1127. https://doi.org/10.1067/S0002-9378(03)00579-9

    Article  Google Scholar 

  4. McCluggage WG (2011) Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 43(5):420–432. https://doi.org/10.1097/PAT.0b013e328348a6e7

    Article  PubMed  Google Scholar 

  5. Shih LM, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164(5):1511–1518. https://doi.org/10.1016/S0002-9440(10)63708-X

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Koshiyama M, Matsumura N, Ikuo K (2014) Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int 93:461

    Google Scholar 

  7. Gross AL, Kurman RJ, Russell V, Shih LM, Visvanathan K (2010) Precursor lesions of high grade serous ovarian oarcinoma: morphological and molecular characteristics. J Oncol ID 126295

  8. Erickson BK, Connor MG, Landen CN (2013) The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol 209(5):409–414. https://doi.org/10.1016/j.ajog.2013.04.019

  9. Clarke BA, Crum CP, Nucci MR et al Protocol for the examination of specimens from patients with carcinoma of the fallopian tube. College of American Pathologists. Based on AJCC/UICC TNM, 7th edition, and FIGO 2006 Annual Report. Available at: http://www.cap.org

  10. Poon C, Hyde S, Grant P, Newman M, Ireland Jenkin K (2016) Incidence and characteristics of unsuspected neoplasia discovered in high-risk women undergoing risk reductive bilateral salpingooophorectomy. Int J Gynecol Cancer 26(8):1415–1420. https://doi.org/10.1097/IGC.0000000000000791

    Article  PubMed  Google Scholar 

  11. National Cancer Institute (2014) Ovarian cancer screening (PDQ_). Available at: http://www.cancer.gov/cancertopics/pdq/screening/ovarian/healthprofessional/allpages

  12. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, Crump DN, Davies SK, Dawnay A, Dobbs S, Fletcher G, Ford J, Godfrey K, Gunu R, Habib M, Hallett R, Herod J, Jenkins H, Karpinskyj C, Leeson S, Lewis SJ, Liston WR, Lopes A, Mould T, Murdoch J, Oram D, Rabideau DJ, Reynolds K, Scott I, Seif MW, Sharma A, Singh N, Taylor J, Warburton F, Widschwendter M, Williamson K, Woolas R, Fallowfield L, McGuire AJ, Campbell S, Parmar M, Skates SJ (2016) Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomised controlled trial. Lancet 387(10022):945–956. https://doi.org/10.1016/S0140-6736(15)01224-6

    Article  PubMed  PubMed Central  Google Scholar 

  13. Cancer Genome Atlas Research (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609–615

    Article  CAS  Google Scholar 

  14. Alsop K, Fereday S, Meldrum C, de Fazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30(21):2654–2663. https://doi.org/10.1200/JCO.2011.39.8545

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Manchanda R, Abdelraheim A, Johnson M, Rosenthal AN, Benjamin E, Brunell C, Burnell M, Side L, Gessler S, Saridogan E, Oram D, Jacobs I, Menon U (2011) Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. Br J Obstet Gynaecol 118(7):814–824. https://doi.org/10.1111/j.1471-0528.2011.02920.x

  16. Hartmann LC, Lindor NM (2016) The role of risk reducing surgery in hereditary breast and ovarian cancer. N Engl J Med 374(5):454–468. https://doi.org/10.1056/NEJMra1503523

    Article  PubMed  CAS  Google Scholar 

  17. Rocca WA, Gazzuola-Rocca L, Smith CY, Grossardt BR, Faubion SS, Shuster LT, Kirkland JL, Stewart EA, Miller VM (2016) Accelerated accumulation of multimorbidity after bilateral oophorectomy: a population-based cohort study. Mayo Clin Proc 91(11):1577–1589. https://doi.org/10.1016/j.mayocp.2016.08.002

    Article  PubMed  PubMed Central  Google Scholar 

  18. NCCN Clinical practice guidelines in oncology. Genetic/familial high risk assessment: breast and ovarian. Updated 7th December 2016. Available at: http://www.nccn.org

  19. SIGN Guidance. Number 135: management of epithelial ovarian cancer. Updated November 2013. Available at: http://www.sign.ac.uk

  20. Domchek S, Friebel T, Neuhausen S, et al. (2011) Is hormone replacement therapy (HRT) following risk-reducing salphingo-oophorectomy (RRSO) in BRCA 1 (B1) and BRCA 2 (B2) mutation carriers associated with an increased risk of breast cancer? J Clin Oncol 29 suppl: abstr 1501

  21. Powell CB, Chen LM, McLennan J et al (2011) Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer 21(5):846–851. https://doi.org/10.1097/IGC.0b013e31821bc7e3

    Article  PubMed  Google Scholar 

  22. Weinberger V, Bednarikova M, Cibula D, Zikan M (2016) Serous tubal intraepithelial carcinoma (STIC)—clinical impact and management. Exp Rev Anticancer Therapy 16(12):1311–1321. https://doi.org/10.1080/14737140.2016.1247699

    Article  CAS  Google Scholar 

  23. Kwon J, Tinker A, Pansegrau G et al (2013) Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol 121(1):14–24. https://doi.org/10.1097/AOG.0b013e3182783c2f

    Article  PubMed  Google Scholar 

  24. Mahon S, McFadden J, Gleeson N, O’Riain C (2016) Would fallopian tube tissue be left behind? Quantitation of tubal-type epithelium within ovary at time of risk reduction salpingo-oophorectomy—implications for ovary conserving strategies. Mod Pathol 29(S2):296A

    Google Scholar 

  25. Kamran MW, Vaughan D, Crosby D, Wahab NA, Saadeh FA, Gleeson N (2013) Opportunistic and interventional salpingectomy in women at risk—a strategy for preventing pelvic serous cancer (PSC). Eur J Obstet Gynecol Reprod Biol 170(1):251–254. https://doi.org/10.1016/j.ejogrb.2013.06.030

    Article  PubMed  CAS  Google Scholar 

  26. Mingels MJ, Roelofsen T, Van der Laak JA et al (2012) Tubal epithelial lesions in alpingo-oophorectomy specimens of BRCA-mutation carriers and controls. Gynecol Oncol 127(1):88–93. https://doi.org/10.1016/j.ygyno.2012.06.015

    Article  PubMed  CAS  Google Scholar 

  27. Vorwergk J (2014) Prophylactic bilateral salpingectomy (PBS) to reduce ovarian cancer risk incorporated in standard premenopausal hysterectomy: complications and re-operation rate. J Cancer Res Clin Oncol 140(5):859–865. https://doi.org/10.1007/s00432-014-1622-6

    Article  PubMed  CAS  Google Scholar 

  28. Polcher M, Hauptmann S, Fotopoulou C et al (2015) Opportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the Kommission Ovar of the AGO. Arch Gynecol Obstet 292(1):231–234. https://doi.org/10.1007/s00404-015-3697-y

    Article  PubMed  Google Scholar 

  29. Venturella R, Lico D, Borelli M et al (2016) 3 to 5 years later: long-term effects of prophylactic bilateral salpingectomy on ovarian function. Minim Invasive Gynecol 13:S1553–S4650

  30. Segev Y, Igbal J, Lubinski J, Hereditary Breast Cancer Study Group et al (2013) The incidence of endometrial cancer in women with BRCA 1 and BRCA 2 mutations: an international prospective cohort study. Gynecol Oncol 130(1):127–131. https://doi.org/10.1016/j.ygyno.2013.03.027

    Article  PubMed  CAS  Google Scholar 

  31. Pennington KP, Walsh T, Lee M, Pennil C, Novetsky AP, Agnew KJ, Thornton A, Garcia R, Mutch D, King MC, Goodfellow P, Swisher EM (2013) BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer 119(2):332–338. https://doi.org/10.1002/cncr.27720

    Article  PubMed  CAS  Google Scholar 

  32. Mc Cluggage WG, Mc Manus DT, Lioe TF, Hill CM (1997) Uterine carcino-sarcoma in association with tamoxifen treatment. Brit J Obstet Gynaecol 104(6):748–775. https://doi.org/10.1111/j.1471-0528.1997.tb11992.x

    Article  CAS  Google Scholar 

  33. Chlebowski R, Rohan T, Manson J et al (2015) Breast cancer after use of oestrogen plus progestin and oestrogen alone: analysis from 2 Women’s Health Initiative Randomised Clinical Trials. JAMA Oncol 1(3):296–305. https://doi.org/10.1001/jamaoncol.2015.0494

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gynaecological Oncology Department, St James’s Hospital, Dublin, Ireland

    Claire Thompson, Ciara McCormick, Waseem Kamran & Noreen Gleeson

  2. Histopathology Department, St James’s Hospital, Dublin, Ireland

    Ciaran O’Riain

  3. Obstetrics and Gynaecology Department, Trinity Centre for Health Sciences, St James’s Hospital, Dublin, Ireland

    Lucy Norris

  4. Medical Oncology Department, St James’s Hospital, Dublin, Ireland

    David Gallagher

Authors
  1. Claire Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ciara McCormick
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Waseem Kamran
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ciaran O’Riain
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lucy Norris
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David Gallagher
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Noreen Gleeson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claire Thompson.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Thompson, C., McCormick, C., Kamran, W. et al. Risk reduction surgery (RRS) for tubo-ovarian cancer in an Irish gynaecological practice: an analysis of indications and outcomes. Ir J Med Sci 187, 789–794 (2018). https://doi.org/10.1007/s11845-017-1717-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-017-1717-6

Keywords

Search

Navigation